Nonresponse to tumor necrosis factor antagonists - is there any point in re-treatment?

被引：13

作者：

Buch, Maya H. ^{[1
]}

Emery, Paul ^{[1
]}

机构：

[1] Leeds Teaching Hosp, Leeds, W Yorkshire, England

来源：

NATURE CLINICAL PRACTICE RHEUMATOLOGY | 2006年 / 2卷 / 06期

关键词：

D O I：

10.1038/ncprheum0210

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

[No abstract available]

引用

页码：288 / 289

页数：2

共 11 条

[1] C-reactive protein as a predictor of infliximab treatment outcome in patients with rheumatoid arthritis - Defining subtypes of nonresponse and subsequent response to etanercept
Buch, MH
Seto, Y
Bingham, SJ
Bejarano, V
Bryer, D
White, J
Emery, P
[J]. ARTHRITIS AND RHEUMATISM, 2005, 52 (01): : 42 - 48
[2] Buch MH, 2003, ANN RHEUM DIS, V62, P181
[3] True infliximab resistance in rheumatoid arthritis:: a role for lymphotoxin α?
Buch, MH
Conaghan, PG
Quinn, MA
Bingham, SJ
Veale, D
Emery, P
[J]. ANNALS OF THE RHEUMATIC DISEASES, 2004, 63 (10) : 1344 - 1346
[4] BUCH MH, 2005, ARTHRITIS RHEUM, V52, pS882
[5] Burmester GR, 2005, ANN RHEUM DIS, V64, P423
[6] Development of anti-TNF therapy for rheumatoid arthritis
Feldmann, M
[J]. NATURE REVIEWS IMMUNOLOGY, 2002, 2 (05) : 364 - 371
[7] FURST D, 2005, ANN RHEUM DIS, V64, pS58
[8] Infliximab and methotrexate in the treatment of rheumatoid arthritis
Lipsky, PE
van der Heijde, DMFM
St Clair, EW
Furst, DE
Breedveld, FC
Kalden, JR
Smolen, JS
Weisman, M
Emery, P
Feldmann, M
Harriman, GR
Maini, RN
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (22) : 1594 - 1602
[9] Binding and functional comparisons of two types of tumor necrosis factor antagonists
Scallon, B
Cai, A
Solowski, N
Rosenberg, A
Song, XY
Shealy, D
Wagner, C
[J]. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2002, 301 (02) : 418 - 426
[10] CHIMERIC ANTI-TNF-ALPHA MONOCLONAL-ANTIBODY CA2 BINDS RECOMBINANT TRANSMEMBRANE TNF-ALPHA AND ACTIVATES IMMUNE EFFECTOR FUNCTIONS
SCALLON, BJ
MOORE, MA
TRINH, H
KNIGHT, DM
GHRAYEB, J
[J]. CYTOKINE, 1995, 7 (03) : 251 - 259

← 1 2 →